dc.contributor.author | Ebrahimi, Ali | |
dc.contributor.author | Sayad, Babak | |
dc.contributor.author | Rahimi, Zohreh | |
dc.date.accessioned | 2020-07-07T14:58:48Z | |
dc.date.available | 2020-07-07T14:58:48Z | |
dc.date.issued | 2020-07-06 | |
dc.identifier.uri | https://doi.org/10.1080/09546634.2020.1789051 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1976 | |
dc.description.abstract | Background: There is concern about susceptibility of psoriatic patients on biologics to coronavirus disease 2019 (COVID-19) and its clinical course. Purpose: The aims of present review were to determine whether the biologic treatment of psoriasis increases the risk of SARS-CoV-2 infection and if biologics affect the clinical course of COVID-19 in these patients. Methods: We searched database of MEDLINE (PubMed) for key term of psoriasis biologic and COVID-19 until June 9, 2020 and all published 14 papers and an experience from Iran (10509 cases) related to the psoriatic patients on biologics and COVID-19 along with relevant papers were summarized. In spite of limitation in some reports, due to some of strengths that will be discussed, all papers were included in this review. Results: According to 8769 medical reports around 0.3% of psoriatic patients had COVID-19 and the rate of hospitalization was 0.1%. No death due to COVID-19 was reported among 10509 patients. Reports indicated psoriatic patients on biologics were not more susceptible to COVID-19 and the severe clinical course of disease. Conclusion: While there is not definitive controlled trial data, the available evidence suggests that patients with psoriasis without COVID-19 can continue the biologic therapy for psoriasis. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Psoriasis | en_US |
dc.subject | Cytokines | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Immunosuppressive Agents | en_US |
dc.title | COVID-19 and psoriasis: biologic treatment and challenges | en_US |
eihealth.country | Others | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | Journal of Dermatological Treatment | en_US |